Skip to main content
Fig. 1 | BMC Urology

Fig. 1

From: A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy

Fig. 1

Area under receiver operating characteristic (AUC) curves are shown to compare performances of EPI in (a) the current cohort (n = 229) with the ERSPC, and PSA alone. The corresponding net benefit analysis for this cohort is shown in b. EPI = ExoDx Prostate (IntelliScore); ERSPC = European Randomized Study of Screening for prostate cancer (risk calculator); PSA = prostate-specific antigen

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us